Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, have entered an option, research and license agreement worth as much as $100 million. The partnership will leverage Dewpoint’s platform for biomolecular condensates and Bayer’s small molecule compound library to develop new treatments for cardiovascular and gynecological diseases.   Currently, approximately 80 percent of the human proteome is considered to be beyond the reach of smal...